glp-1 obesity drug news oct 21 2025 Weight Loss Enforcement in 2025: State Attorneys General Step into a Growing Regulatory Gap 2024 was a record year

The highest rates of GLP-1 medication usage are in the Southeastern and Midwestern states

Maria Carrillo, chief science officer and medical affairs lead for the Alzheimers Association, which was not involved with the research

is particularly important because it directly examines semaglutide use in older adults with T2DM with an explicit focus on sarcopenia and provides relatively long-term outcomes [60]

Similarly, individuals who have a history of gastrointestinal issues may want to avoid Mounjaro. Smith added that you should talk with your doctor about your medical history to determine which drug may be better for you

(available at: [Google Scholar] 69.Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, Chawla S, Chowdhury K, Skene SS, Greig NHet al

This happens to some GLP-1 users who get full fast and might not eat enough food to get all the protein their body needs, causing a problem: losing valuable muscle along with fat